Google+ Facebook Twitter Twitter

Faecal microbiota transplant for C. diff

In the first comprehensive US evidence-based guideline on the use of faecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends faecal microbiota transplant (FMT) for most patients with recurrent Clostridioides difficile (C. diff) infection.

clostridioides difficile bacteria-Image Credit | Science Photo Library - c0016337

“Using faecal microbiota transplant, we take a stool from a healthy donor and transfer it to the colon of the person with recurrent C. diff, restoring balance to their gut microbiome,” said author Dr Anne Peery.

“FMT is a safe and effective treatment with enough scientific evidence to be offered to most patients with two or more C. diff recurrences.” 

In the US, nearly half a million people each year experience C. diff. One in six of those people will deal with a C. diff recurrence within two to eight weeks. 

For patients with recurrent C. diff infection at a high risk of recurrence, the AGA recommends the use of FMT-based therapy after completing a course of antibiotics. Only severely immunocompromised patients (such as neutropenic patients or those who have received a bone marrow transplant) are excluded from the recommendation.

For hospitalised patients with severe C. diff infection, the AGA recommends the use of conventional FMT following standard-of-care antibiotic therapy in select patients if there is no improvement.

FMT therapies are not recommended as a treatment for inflammatory bowel diseases or irritable bowel syndrome.

Image Credit | Science Photo Library

Related Articles

Doctor's hands vaccinating a woman stock photo CREDIT-iStock-1444188743

A universal vaccine?

Scientists have demonstrated a new, RNA-based vaccine strategy that is effective against any strain of a virus and can be used safely even by babies and the immunocompromised.

Two Scientist Microscope images and video- istock-1363238207

Enzymes open new path to universal donor blood

The quest to develop universal donor blood has taken a decisive step forward, it is claimed.

Pseudomonas aeruginosa bacteria - CREDIT - Science-Photolibrary-f0280202

New five-year plan to combat antimicrobial resistance

The government’s national action plan will commit the UK to reducing its use of antimicrobials – such as antibiotics, antifungals and antivirals – in humans and animals, strengthen surveillance of drug-resistant infections before they emerge and incentivise industry to develop the next generation of treatments.


Sponsored: Time is of the essence in the management of sepsis

Every year, 49 million people acquire sepsis. Time is of the essence for appropriate therapy as the key driver of clinical outcomes.